Current Therapies That Modify Glucagon Secretion: What Is the Therapeutic Effect of Such Modifications?
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Current Therapies That Modify Glucagon Secretion : What Is the Therapeutic Effect of Such Modifications? / Grøndahl, Magnus F.; Keating, Damien J.; Vilsbøll, Tina; Knop, Filip K.
I: Current Diabetes Reports, Bind 17, Nr. 12, 128, 2017.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Current Therapies That Modify Glucagon Secretion
T2 - What Is the Therapeutic Effect of Such Modifications?
AU - Grøndahl, Magnus F.
AU - Keating, Damien J.
AU - Vilsbøll, Tina
AU - Knop, Filip K.
PY - 2017
Y1 - 2017
N2 - Purpose of Review: Hyperglucagonemia contributes significantly to hyperglycemia in type 2 diabetes and suppressed glucagon levels may increase the risk of hypoglycemia. Here, we give a brief overview of glucagon physiology and the role of glucagon in the pathophysiology of type 2 diabetes and provide insights into how antidiabetic drugs influence glucagon secretion as well as a perspective on the future of glucagon-targeting drugs. Recent Findings: Several older as well as recent investigations have evaluated the effect of antidiabetic agents on glucagon secretion to understand how glucagon may be involved in the drugs’ efficacy and safety profiles. Based on these findings, modulation of glucagon secretion seems to play a hitherto underestimated role in the efficacy and safety of several glucose-lowering drugs. Summary: Numerous drugs currently available to diabetologists are capable of altering glucagon secretion: metformin, sulfonylurea compounds, insulin, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter 2 inhibitors and amylin mimetics. Their diverse effects on glucagon secretion are of importance for their individual efficacy and safety profiles. Understanding how these drugs interact with glucagon secretion may help to optimize treatment.
AB - Purpose of Review: Hyperglucagonemia contributes significantly to hyperglycemia in type 2 diabetes and suppressed glucagon levels may increase the risk of hypoglycemia. Here, we give a brief overview of glucagon physiology and the role of glucagon in the pathophysiology of type 2 diabetes and provide insights into how antidiabetic drugs influence glucagon secretion as well as a perspective on the future of glucagon-targeting drugs. Recent Findings: Several older as well as recent investigations have evaluated the effect of antidiabetic agents on glucagon secretion to understand how glucagon may be involved in the drugs’ efficacy and safety profiles. Based on these findings, modulation of glucagon secretion seems to play a hitherto underestimated role in the efficacy and safety of several glucose-lowering drugs. Summary: Numerous drugs currently available to diabetologists are capable of altering glucagon secretion: metformin, sulfonylurea compounds, insulin, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter 2 inhibitors and amylin mimetics. Their diverse effects on glucagon secretion are of importance for their individual efficacy and safety profiles. Understanding how these drugs interact with glucagon secretion may help to optimize treatment.
KW - Alpha cell regulation
KW - Diabetes
KW - Glucagon secretion
KW - Glucagon-like peptide 1
KW - Hyperglucagonemia
KW - Incretin therapy
U2 - 10.1007/s11892-017-0967-z
DO - 10.1007/s11892-017-0967-z
M3 - Review
C2 - 29080075
AN - SCOPUS:85032372314
VL - 17
JO - Current Diabetes Reports
JF - Current Diabetes Reports
SN - 1534-4827
IS - 12
M1 - 128
ER -
ID: 189360947